GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/IBD/Ulcerative Colitis: Is a 10-Week Steroid Taper Better Than 6 Weeks?: JCC Plus | September 2026
5

Ulcerative Colitis: Is a 10-Week Steroid Taper Better Than 6 Weeks?: JCC Plus | September 2026

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated September 1, 2026

Introduction:

Corticosteroids remain widely used for induction in moderate-to-severe UC, yet how quickly they should be tapered remains surprisingly uncertain. This Y-ECCO review examines an RCT comparing 10-week versus 6-week prednisolone courses after initial steroid response.

Why is this topic important?

UC guidelines provide limited evidence-based guidance on steroid tapering.

Rapid tapering may permit relapse before slower maintenance therapies become effective.

Longer exposure, however, increases steroid toxicity and risk of adrenal suppression.

The optimal taper may depend on the maintenance therapy used.

Key Takeaways:

94 steroid-responsive patients were randomized to a 10-week or 6-week taper.

At 6 months, steroid-free remission was 37% vs 17%, favoring the longer taper.

Median time to relapse was longer: 5 vs 2 months.

Overall relapse rates, endoscopic healing, histologic remission, and safety were not significantly different.

Most patients received 5-ASA and thiopurines, making the findings particularly relevant when using slower-acting conventional maintenance.

A prolonged taper may be less necessary when rapidly effective advanced therapy is started early.

The small, single-centre trial and statistical limitations make the evidence suggestive rather than definitive.

Courses exceeding 4 weeks should also consider adrenal insufficiency and steroid stewardship.

Bottom Line:

A 10-week taper may improve steroid-free remission compared with 6 weeks when conventional maintenance therapy is used. Rather than one fixed schedule, steroid tapering should increasingly reflect the speed and effectiveness of the accompanying maintenance therapy.

Related Q&A

06

Multiplex Stool PCR May Prevent Unnecessary Treatment Escalation During IBD Flares: FG | September 2026

Introduction: Enteric infections can closely mimic an IBD flare, creating a difficult clinical question: infection or active inflammation? This meta-analysis evaluated whether stool multiplex PCR (MPCR) improves pathogen...

07

PROFILE at 5 Years: Treating Crohn’s Early: The Lancet Gastroenterology & Hepatology | September 2026

What Did the Study Find? PROFILE followed newly diagnosed Crohn’s disease patients originally randomized to top-down infliximab + immunomodulator or conventional step-up therapy. At ~5 years, Crohn’s-related surgery...

08

VIVID-2: Mirikizumab Remains Effective Through 2 Years—and Some Late Nonresponders Can Be Rescued: CGH | September 2026

Introduction: Long-term durability and management of incomplete response are important when positioning IL-23 therapy in Crohn’s disease. VIVID-2 evaluated mirikizumab through 104 weeks, including IV reinduction in patients...

09

RISANCROHN: Risankizumab Works in Highly Refractory Crohn’s—but Earlier Positioning May Matter: AP & T | September 2026 | Multicentre Real-World Study

Introduction: Risankizumab, an IL-23p19 inhibitor, is an effective therapy for Crohn’s disease, but real-world outcomes in heavily pretreated patients are important for treatment positioning. RISANCROHN evaluated its effectiveness...

10

Localised Ileocaecal Crohn’s Disease: Early Surgery Deserves a Place Beside Biologics: Colorectal Disease | September 2026 | Systematic Review & Meta-analysis

Introduction: Biologics are commonly used early in Crohn’s disease, while surgery is often reserved for complications or treatment failure. This meta-analysis compared early ileocaecal resection with biologic-first therapy...

11

Ozanimod Shows Real-World Effectiveness in UC, but Week-48 Results Need Cautious Interpretation: Medicina | September 2026

Introduction Ozanimod is an oral sphingosine-1-phosphate (S1P) receptor modulator approved for moderate-to-severe ulcerative colitis (UC), with efficacy established in the phase 3 True North program. However, real-world evidence...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer